KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.99

Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.

S Lonardi, H-J Lenz, E Elez, L H Jensen, E Van Cutsem, Y Touchefeu, R Rocio Garcia-Carbonero, D Tougeron, G A Mendez, M Schenker, C de la Fouchardière, M L Limón Mirón, T Yoshino, J Li, J L Manzano Mozo, L Dahan, G Tortora, M Chalabi, E Goekkurt, M I Braghiroli, R Joshi, T Cil, F Aubin, V Raparthi, A Wang, S Rodriguez, E Cela, L Li, R Tam, L Jin, T André

Ann Oncol S0923-7534(26)06652-4

PMID42926106
PMCID-
DOI10.1016/j.annonc.2026.09.009
发表日期2026-10-24
入排依据:Eligible as an original formal-result Phase III randomized oncology trial with drug intervention and time-to-event efficacy endpoints.
摘要

摘要

BACKGROUND: The phase III CheckMate 8HW trial met its dual primary endpoints of superior progression-free survival (PFS) with nivolumab plus ipilimumab (NIVO + IPI) versus chemotherapy [first-line (1L)] and versus NIVO (all lines) in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC). We report prespecified final overall survival (OS) analyses and updated efficacy outcomes. PATIENTS AND METHODS: Immunotherapy-naïve adults with mCRC across different lines and MSI-H/dMMR by local testing were randomly assigned 2 : 2 : 1 to NIVO (240 mg) plus IPI (1 mg/kg) once every 3 weeks for four doses and then NIVO 480 mg once every 4 weeks; NIVO (240 mg) once every 2 weeks (six doses) and then 480 mg once every 4 weeks; or chemotherapy ± targeted therapies. Secondary endpoints include PFS in NIVO + IPI versus NIVO (1L) and OS and objective response rate in the centrally confirmed MSI-H/dMMR population. RESULTS: In total, 839 patients across all lines were randomly assigned; efficacy analyses were conducted in those with centrally confirmed MSI-H/dMMR. Median follow-up across all lines and treatment groups was 68.0 months (range 37.6-81.4 months). NIVO + IPI demonstrated significant OS benefit compared with NIVO across all lines [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.46-0.82, P = 0.0009] and with chemotherapy in 1L (HR 0.37, 95% CI 0.24-0.57, P < 0.0001). Clinically meaningful OS benefit was noted with 1L NIVO + IPI versus NIVO (HR 0.66, 95% CI 0.44-0.99, P = 0.0432), not meeting the prespecified threshold for significance (P < 0.006). PFS continued to favor NIVO + IPI across all three comparisons: NIVO (all lines; HR 0.60), chemotherapy (1L; HR 0.21), and NIVO (1L; HR 0.68). Grade 3/4 treatment-related adverse events occurred in 78 (22%) versus 50 (14%) patients treated with NIVO + IPI versus NIVO across all lines, with no new safety concerns or additional treatment-related deaths from the previous follow-up. CONCLUSIONS: NIVO + IPI showed significant OS benefit compared with NIVO across all lines and with chemotherapy in 1L, while providing a clinical OS benefit versus NIVO in 1L, reinforcing its standard-of-care status in MSI-H/dMMR mCRC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。